Inventiva S.A. announced the receipt of the €25 million payment under the first tranche of the unsecured loan agreement executed with the European Investment Bank on May 16, 2022 with a maturity date of December 2026. As previously announced, the Finance Contract provides funding in two tranches of €25 million each, which are both subject to the completion of certain conditions precedent. Any drawings under the terms of the Finance Contract that have not been disbursed within 36 months from the signing of the Finance Contract, (i.e., before May 16, 2025), cannot be completed at a later date.

There is no assurance that the Company will be able to satisfy the conditions precedent for the drawing of the second tranche. The disbursement of the first tranche (with 8% interest capitalized annually, a maturity of 4 years and a repayment in fine) was subject to, among other conditions, (i) the Company issuing warrants to EIB in accordance with the terms and conditions of the warrants agreements entered into July 1, 2022, and (ii) the Company's receipt from the date of the Finance Contract of an aggregate amount of €18 million, paid either in exchange for new shares of the Company or through the receipt of upfront or milestone payments. On June 15, 2022, the Company raised €9.3 million through a capital increase under its ATM program.

On November 4, 2022, the Company received an upfront payment of $12 million under its collaboration agreement with Sino Biopharm. On November 28, 2022, the Company issued 2,266,023 warrants to EIB, in accordance of the terms of the 25th resolution of the combined general meeting of shareholders of May 19, 2022 and Article L.225-138 of the French Commercial Code, as a condition to the financing of the first tranche, representing approximately 5.4% of the Company's share capital outstanding as of the date hereof. The exercise price of the warrants is equal to €4.0152 and corresponds to 95% of the volume-weighted average price of the Company's shares on the regulated market of Euronext Paris during the last trading session preceding the decision to issue the warrants.